EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies

Ombretta Melaiu, Gianluca Vanni, Ilaria Portarena, Chiara Adriana Pistolese, Lucia Anemona iD, Silvia Pomella iD, Roberto Bei iD, Oreste Claudio Buonomo, Mario Roselli iD, Alessandro Mauriello iD, Giovanni Barillari iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ombretta Melaiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have a modest clinical activity when administered as monotherapy against breast cancer (BC), the most common malignancy in women. Novel combinatorial strategies are currently being investigated to overcome resistance to ICIs and promote antitumor immune responses in a greater proportion of BC patients. Recent studies have shown that the BC abnormal vasculature is associated with immune suppression in patients, and hampers both drug delivery and immune effector cell trafficking to tumor nests. Thus, strategies directed at normalizing (i.e., at remodeling and stabilizing) the immature, abnormal tumor vessels are receiving much attention. In particular, the combination of ICIs with tumor vessel normalizing agents is thought to hold great promise for the treatment of BC patients. Indeed, a compelling body of evidence indicates that the addition of low doses of antiangiogenic drugs to ICIs substantially improves antitumor immunity. In this review, we outline the impact that the reciprocal interactions occurring between tumor angiogenesis and immune cells have on the immune evasion and clinical progression of BC. In addition, we overview preclinical and clinical studies that are presently evaluating the therapeutic effectiveness of combining ICIs with antiangiogenic drugs in BC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasmsHumansFemaleImmune Checkpoint InhibitorsNeovascularization, PathologicAngiogenesis InhibitorsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

angiogenesisantitumor immunitybreast cancerimmune checkpoint inhibitorsimmunosuppressiontumor microenvironmentvessel normalization

Substanzen

Immune Checkpoint InhibitorsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
  • Breast Unit, Department of Surgical Science, PTV Policlinico "Tor Vergata" University, Via Montpellier 1, 00133 Rome, Italy.
  • Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
  • Department of Diagnostic and Molecular Imaging, Interventional Radiology and Radiotherapy, University Hospital of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.
  • Anatomic Pathology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

ORCID-Profile: Lucia Anemona, Silvia Pomella, Roberto Bei, Mario Roselli, Alessandro Mauriello, Giovanni Barillari

Förderung

  • Italian Ministry of Health

Zitieren

APA

Melaiu, O., Vanni, G., Portarena, I., Pistolese, C. A., Anemona, L., Pomella, S., Bei, R., Buonomo, O. C., Roselli, M., Mauriello, A., & Barillari, G. (2023). The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043226

Vancouver

Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, et al. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043226

BibTeX
@article{Melaiu2023,
  author = {Melaiu, Ombretta and Vanni, Gianluca and Portarena, Ilaria and Pistolese, Chiara Adriana and Anemona, Lucia and Pomella, Silvia and Bei, Roberto and Buonomo, Oreste Claudio and Roselli, Mario and Mauriello, Alessandro and Barillari, Giovanni},
  title = {The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043226}
}
Kostenlos starten →